Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
19,725,140
-
Shares change
-
+879,731
-
Total reported value, excl. options
-
$242,759,481
-
Value change
-
+$18,076,577
-
Number of buys
-
29
-
Number of sells
-
-17
-
Price
-
$15.68
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2016
66 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q3 2016.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19,725,140 shares
of 165,547,872 outstanding shares and own 11.9% of the company stock.
Largest 10 shareholders include FMR LLC (5,443,262 shares), Canaan Partners IX LLC (4,244,381 shares), PUTNAM INVESTMENTS LLC (1,369,801 shares), DEERFIELD MANAGEMENT CO (943,433 shares), VANGUARD GROUP INC (784,646 shares), Tekla Capital Management LLC (756,090 shares), Redmile Group, LLC (714,692 shares), BVF INC/IL (591,813 shares), VHCP Management II, LLC (577,831 shares), and BlackRock Fund Advisors (557,851 shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.